Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and Esophageal Neoplasms

sorafenib has been researched along with Esophageal Neoplasms in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (25.00)29.6817
2010's5 (41.67)24.3611
2020's4 (33.33)2.80

Authors

AuthorsStudies
Dai, B; Feng, J; Guo, C; Hou, Z; Li, X; Lin, H; Liu, P; Niu, Y; Qi, M; Wang, H; Wang, O; Zhang, D; Zhou, H1
Feng, YF; Lei, YY; Liu, W; Luo, HH; Yang, HS; Zheng, SY1
Fu, L; Ma, Z; Wang, B; Wang, H; Yu, G; Zhu, T1
Chen, K; Feng, B; Hu, H; Hu, J; Liu, Q; Lu, Y1
Jiang, L; Liu, H; Liu, X; Shi, G; Wang, X1
Berger, M; Bouvier, N; Capanu, M; Herrera, JM; Ilson, DH; Janjigian, YY; Ku, GY; Socci, ND; Tang, LH; Vakiani, E; Viale, A1
Bissonnette, M; Cerda, S; Chumsangsri, A; Delgado, JS; Dougherty, U; Fichera, A; Lichtenstein, L; Mustafi, R; Yee, J1
Bissonnette, M; Chumsangsri, A; Cohen, EE; Delgado, J; Keswani, RN; Mustafi, R1
Shoemaker, RH1
Altorki, NK; Alvarez, H; Beer, DG; Boonstra, JJ; Chaves, P; Darnton, SJ; Dinjens, WN; Eshleman, JR; Klimstra, DS; Lin, L; Pereira, AD; Ribeiro, C; Roque, L; Schrump, DS; Shimada, Y; Tang, LH; Tilanus, HW; van Dekken, H; van Marion, R1
Cunningham, D; Okines, AF; Reynolds, AR1
Di Fiore, F; Michel, P1

Reviews

1 review(s) available for sorafenib and Esophageal Neoplasms

ArticleYear
Targeting angiogenesis in esophagogastric adenocarcinoma.
    The oncologist, 2011, Volume: 16, Issue:6

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Disease Models, Animal; Disease-Free Survival; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A

2011

Trials

1 trial(s) available for sorafenib and Esophageal Neoplasms

ArticleYear
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Survival Analysis

2015

Other Studies

10 other study(ies) available for sorafenib and Esophageal Neoplasms

ArticleYear
The deubiquitinating enzyme USP20 regulates the stability of the MCL1 protein.
    Biochemical and biophysical research communications, 2022, 02-19, Volume: 593

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Endopeptidase Complex; Protein Stability; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Ubiquitin; Ubiquitin Thiolesterase; Ubiquitination

2022
Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration.
    BMC bioinformatics, 2022, Sep-30, Volume: 23, Issue:1

    Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gefitinib; Humans; Oxidative Stress; Prognosis; Sorafenib; Tumor Microenvironment; Tumor Suppressor Protein p53

2022
E2F1 Reduces Sorafenib's Sensitivity of Esophageal Carcinoma Cells via Modulating the miR-29c-3p/COL11A1 Signaling Axis.
    Current molecular pharmacology, 2024, Volume: 17, Issue:1

    Topics: Animals; Apoptosis; Carcinoma; Esophageal Neoplasms; Signal Transduction; Sorafenib

2024
Inhibition of Apoc1 reverses resistance of sorafenib by promoting ferroptosis in esophageal cancers.
    Gene, 2024, Jan-20, Volume: 892

    Topics: Animals; Apolipoprotein C-I; Esophageal Neoplasms; Ferroptosis; Mice; Mice, Nude; Reactive Oxygen Species; Sorafenib

2024
Tiam1 siRNA enhanced the sensitivity of sorafenib on esophageal squamous cell carcinoma in vivo.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Guanine Nucleotide Exchange Factors; Humans; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib; T-Lymphoma Invasion and Metastasis-inducing Protein 1; Xenograft Model Antitumor Assays

2014
Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells.
    Digestive diseases and sciences, 2008, Volume: 53, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin E; Esophageal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyridines; Sorafenib; STAT3 Transcription Factor

2008
Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2008, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Analysis of Variance; Barrett Esophagus; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Esophageal Neoplasms; Humans; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Probability; Protein Kinase Inhibitors; Pyridines; Reference Values; Sorafenib

2008
Identification of bona fide esophageal adenocarcinoma cell lines.
    Journal of the National Cancer Institute, 2010, Feb-24, Volume: 102, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Clinical Trials as Topic; DNA Fingerprinting; Esophageal Neoplasms; Humans; National Institutes of Health (U.S.); Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tandem Repeat Sequences; United States

2010
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
    Journal of the National Cancer Institute, 2010, Feb-24, Volume: 102, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Biomedical Research; Carcinoma; Carcinoma, Large Cell; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; DNA Fingerprinting; Esophageal Neoplasms; Humans; Lung Neoplasms; National Institutes of Health (U.S.); Niacinamide; Oligonucleotides; Oligopeptides; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Stomach Neoplasms; Tandem Repeat Sequences; Telomerase; United States

2010
[News in digestive oncology].
    Bulletin du cancer, 2008, Volume: 95, Issue:1

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardia; Colonic Neoplasms; Combined Modality Therapy; Digestive System Neoplasms; Esophageal Neoplasms; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms

2008